Expression And Clinical Significance Of Midkine In Specimens And Serum In Breast Cancer

Objective: To investigate the expression of midkine and serum midkineconcentration and the relationship between midkine and clinicopathological characteristics in breast cancerMethods: The expression of MK and MVD of breast cancer specimens taken from 60 breast cancer patients and 20 benign breast tumor patients were examined by immunohistochemical S-P method and Envision method. Tissue was taken from formalin fixation and paraffin embedment breast tumor specimens. meanwhile,S-MK was measured by enzyme-linked immunosorbent assay in 20 healthy controls ,20 patients with benign breast disease,60 patients with breast cancer before and after surgery. Crrelated the results with other parameters which included age of onset, menstrual status, tumor size, clinical TNM phase, histological grading, xillary nodal status, levels of estrogen receptor (ER) and progesterone receptor (PR).Results: (1) The positive expression rate of MK was 78.3% (47/60) in breast cancer and 0(0/20) in benign tumor, MK located in the cytoplasm, The expression of MK was positively correlated with clinical TNM phase (p<0.05) , histological grading (p<0.05) , axillary lymph nodes metastases (p<0.05)and tumor size (p<0.05), which was no correlated with ER , PR, age, menstrual status respectively (p > 0.05).(2) The S-Mk values in patients with breast cancer before surgery were significantly higher than those in patients with breast cancer after surgery or breast benign disease or healthy controls (692. 30 ± 137. 84pg/ml vs 246. 47 ± 38. 80pg/ml or 444. 55 ± 22. 22pg/ml or 431. 40±26. 69pg/ml), the S-MK values in patients with tumor reoccur or metastasis were976. 50 ± 76. 49pg/ml, The high preoperative S-MK was associated with clinical TNM phase , histological grading , axillary lymph nodes metastases and tumor size.